Abstract: A composition for increasing dermal nitric oxide comprises in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder suspended in a base suitable for application to the skin of a user. The composition may be formed by providing the base suitable for application to the skin of a user and suspending within the base, in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder.

Abstract: Purification of the liver and removal of toxins from the liver may be improved through the ingestion of an herbal supplement containing a specific composition of materials. The herbal supplement contains an effective amount of Echinacea extract, pin pollen extract, royal jelly extract, Crataegus pinnatifida extract, Ziziphus jujuba Mill. extract, and Ginseng extract. The pin pollen extract contains a specific mixture of four flavonoids. The mixture of four flavonoids contains 37.21 percent of a first flavonoid, 22.61 percent of a second flavonoid, 14.94 percent of a third flavonoid, and 25.24 percent of a fourth flavonoid.

Abstract: The present invention relates to a product containing an extract of Rhodiola and an extract of Astragalus as products to be combined for simultaneous administration, separately or staggered over time, in the treatment of a neurodegenerative disease, and in particular for the treatment of Alzheimer's disease and Parkinson's disease.

Abstract: A method of treating or preventing postpartum blues or depression is described, comprising administering to a subject in need thereof: an antioxidant source; a tryptophan composition comprising from 1.0 g to 5.0 g of tryptophan; and a tyrosine composition comprising from 2.0 g to 50 g of tyrosine. The antioxidant source may comprise a food or an extract derived from such a food as grapes, berries such as blueberries, citrus fruit, pomegranate, tomato, squash, carrot, sweet potato, dark green vegetables, beets, leafy vegetables, Brassica oleracea vegetables, peppers, melons, pineapples, lentils, plant oils, and/or tree nuts.

Abstract: The invention concerns a solid feed composition for use as nourishment for bees and for the prevention and treatment of acariosis, and, in particular, of infestation by Varroa destructor, as well as the relative treatment method, comprising: a) nutritional and tonic ingredients, consisting of algae containing vegetal proteins and yeasts; sugars and lower organic acids; b) natural antioxidants and antiseptics contained in the extracts of Origanum vulgare and of Pelargonium graveolens or essential oil of geranium and in the essential extracts of one or more aromatic or medicinal plants selected from: Crocus sativus, Monarda citriodora, Melissa officinalis, Myristica fragrans, and Origanum majorana; and c) curative substances for bees, comprising at least one of thymol and essential extracts of Thymus vulgaris, and at least one of oxalic acid, extracts of Aloe vera or Aloe arborescens, geraniol and extracts of Beta vulgaris cv. altissima, and mixtures of two or more of the same.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present invention relates to a biologically active supplement formulated in an oral dosage form comprising nutraceutically effective amounts of an extract of Usnea barbata lichen, three-lobe beggarticks herb and common barberry berries and having an over-cumulative antibacterial, including bactericidal, action against the wide range of pathogens and conditional human pathogens, as well as over-cumulative antifungal action, including fungistatic and fungicidal actions. In addition, the supplement can comprise black elder berry extract, Baikal skullcap root extract, and fermented black garlic powder. The biologically active supplement of the invention can be used for enhancement of the general non-specific resistance of the body and for prevention or adjuvant therapy of the wide range of bacterial and fungal infections.

Abstract: The present disclosure relates to a composition containing a Paeoniae radix extract as an active ingredient. The composition may alleviate inappetence, weight loss, muscle loss and fatigue and inhibit hematopoietic toxicity. Thus, the composition may be effectively used for the prevention, alleviation or treatment of cachexia and muscle loss.

Abstract: An anti-microbial formulation of native ingredients for human and non-human vertebrate animal feeds, feed supplements/additives, or for direct doses to replace in whole or supplement traditional anti-microbial with side-effects such as allergies, microbial-resistance, and drug-interactions with non-toxic, side-effect free native anti-microbial for all vertebrates. The invention comprises of non-toxic, side-effect free native substances amalgamations having anti-microbial properties for food additives, food supplements, or direct doses. Furthermore, these native formulas can be use with or without other prescription or nonprescription anti-microbial medications. We describe the method of manufacture and also the process of use for this amalgamates.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

Abstract: The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency related side effects, wherein said composition comprises administering a therapeutically effective amount of a Gn RH antagonist to a patient in need of said treatment, and wherein said amount of Gn RH antagonist is sufficient for providing a mean endogenous serum estradiol level of between about 20 pg/ml and 60 pg/ml, preferably between 30 pg/ml and 50 pg/m, in said patient in a treatment period of at least four weeks, without relying on “add-back” therapy. Said composition and method is simple, effective and will accordingly both increase patient acceptance and compliance of therapy.

Abstract: The present invention provides pharmaceutical compositions of teixobactin that are capable of preventing gelation of teixobactin. The pharmaceutical compositions comprise teixobactin and a pegylated phospholipid. The present invention also provides methods of preparing the pharmaceutical compositions of teixobactin and methods of treating a subject using the pharmaceutical compositions of teixobactin.

Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.

Abstract: This invention relates to peptide-exchange proteins comprising the luminal domain of TAP-binding protein-related (TAPBPR), which functions as a MHC class I peptide-exchange catalyst when presented to mammalian cells either as a soluble extracellular protein or as a membrane bound cell surface protein. This may be useful in modulating immune responses, including for example loading immunogenic peptide onto tumours or other disease cells to induce their recognition by T cells. Peptide-exchange proteins and methods for their use are provided.

Abstract: A novel antimicrobial peptide derived from LL37 peptide has not only an excellent antimicrobial activity for Gram-positive bacteria, Gram-negative bacteria, and antibiotic tolerant bacteria but also low cytotoxicity for cells derived from mouse or human. It can be advantageously used as an effective component of antimicrobial antibiotics, cosmetic composition, food additive, animal feed additive, biopesticides, and quasi-drug.

Abstract: Disclosed is the in vitro use of at least one lectin for marking cancer stem cells of hormone-dependent cancer target organs, selected from the lectins Maackia amurensis lectin II (MAH-II), Euonymus europaeus lectin (EEL), Psophocarpus tetragonolobus lectin I (PTL-I) and Griffonia simplicifolia lectin II (GSL-II), in particular at least two lectins selected from MAH-II, EEL, PTL-I and GSL-II, in particular the two lectins MAH-II and EEL, in order to obtain cancer stem cells of labeled hormone-dependent cancer target organs in a biological sample.

Abstract: The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

Abstract: Provided are compositions including a CPNE4 protein or a polynucleotide encoding thereof, a pharmaceutical composition, a quasi-drug composition, a dietary supplement, and a health functional food composition. A method for preventing or treating dentin-dental disease or periodontal disease and a method and a method for promoting regeneration of hard tissue including dentin, bone and cementum, and/or pulp tissue are disclosed.

Abstract: The invention is directed to a method for diagnosing and treating a pulmonary lung disease by detecting a mutant S100A3 protein associated with pulmonary lung disease and by treating a subject with a functional S100A3 protein.

Abstract: The present invention relates to methods for treatment of capillary leak syndrome and acute respiratory distress syndrome using CXCL12 peptides, specifically a constitutively monomeric CXCL12 peptide or a CXCL12 locked dimer polypeptide.

Abstract: The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject, comprising administering to the subject an effective amount of a compound comprising ghrelin.

Abstract: Disclosed herein is a pharmaceutical composition containing a recombinant human GLP-1 peptide and use thereof. The human GLP-1 peptide and the pharmaceutical composition can be used for preventing or treating obesity, bulimia, and/or overweight. Other related uses include weight management (e.g. inducing weight loss), slowing stomach emptying, increasing satiety, etc.

Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.

Abstract: Provided herein are compositions and methods for facilitating or enhancing delivery of nucleic acids, such as synthetic mRNAs, into cells or tissues. Such compositions and methods may include use of a targeting moiety-conjugated, such as an N-acetylgalactosamine (GalNAc)-conjugated, oligonucleotide to facilitate or enhance delivery.

Abstract: The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME).

Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.

Abstract: Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to one or more target nucleic acid sequences in a retrovirus genome.

Abstract: The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses.

Abstract: The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.

Abstract: The present disclosure provides a Farmington virus formulated to induce an immune response in a mammal against a tumour associated antigen. The Farmington virus may express an antigenic protein that includes an epitope from the tumour associated antigen. The Farmington virus may be formulated in a composition where the virus is separate from an antigenic protein that includes an epitope from the tumour associated antigen. The present disclosure also provides a prime:boost therapy for use in inducing an immune response in a mammal. The boost includes a Farmington virus, or a composition that includes a Farmington virus.

Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

Abstract: The present invention relates to the field of tuberculosis vaccines, and specifically relates to a tuberculosis vaccine, a preparation method thereof, and a use thereof. To address the problem of existing vaccines being unsuitable for patients having weak immunity, the present invention provides a preparation method for a tuberculosis vaccine: first obtaining mycobacterium single cell bacteria, and using low dosage radiation to irradiate cyclically the mycobacterium single cell bacteria, so as to obtain the tuberculosis vaccine. The present invention completely retains all of the antigen characteristics of the bacteria, and can more rapidly stimulate stronger specific immune responses, thereby achieving effective and long-lasting immunity. The vaccine prepared using the present invention has low toxicity, is rapid-acting and safer, and can be used for the prevention and treatment of tuberculosis for people having immunodeficiency.

Abstract: The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.

Abstract: A novel K (capsular antigen) serotype of Vibrio parahaemolyticus and an application thereof are provided. A novel K (capsular antigen) serotype of Vibrio parahaemolyticus, which was deposited at the China General Microbiological Culture Collection Center (Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing) on Feb. 20, 2019, with a deposit number of CGMCC No. 17249, wherein the K epitope of the Vibrio parahaemolyticus has a sequence set forth in Sequence No. 1. The novel K serum is highly specific, and can be used to conveniently and quickly detect a novel K serotype of Vibrio parahaemolyticus (O4:KUT-recAin) which has a rising infection rate in recent years. It provides important detection techniques for the pathogen diagnosis, monitoring and prevention of infectious diarrhea.

Abstract: A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

Abstract: Disclosed are vaccines capable of achieving protection against RSV while avoiding vaccine-enhanced disease (VED). In particular, vaccine constructs have been molecularly designed and genetically engineered to comprise RSV fusion (F) protein displayed on the surface of a particle, such as a virus-like particles (VLP) and low temperature-prepared split RSV. In some embodiments, the RSV F protein is in a pre-fusion F conformation. Also disclosed a variants and combinations of split RSV and RSV F DNA vaccine with pre-fusion F and enhanced efficacy. In addition, disclosed split RSV vaccines containing pre-fusion F conformation and combination adjuvants MPL and CpG.

Abstract: An antigenic short peptide includes 11 to 15 amino-acid residues and has an ability to induce antibody against influenza virus. The sequence of the antigenic peptide is selected from hemagglutinin (HA). The antigenic peptide includes the sequence of JJ (SEQ ID NO:2), JJ-1 (SEQ ID NO:3), JJ-2 (SEQ ID NO:4), JJ-3 (SEQ ID NO:5) or JJ-4 SEQ ID NO:6). A method for inducing a broad-spectrum immunity against influenza viruses includes administering a vaccine to a subject, wherein the vaccine comprises one of the above antigenic peptide.

Abstract: The invention is directed to HIV-1 envelope proteins and peptides, and compositions comprising the same to increase the breadth of vaccine coverage of the V1 V2 env region of clade C HIV-1.

Abstract: The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

Abstract: The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.

Abstract: The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R1 is a saturated C8-C16 aliphatic chain having a =0 on C1, said chain being free from —OH substituents on C3, wherein R2 is a saturated C8-C16 aliphatic chain having a ?O on C1, said chain being free from —OH substituents on C3, wherein R3 is a saturated C8-C16 aliphatic chain having a ?O on C1, said chain being free from —OH substituents on C3; wherein R4 is a hydrogen atom (H) or a phosphate group (PO42?).

Abstract: The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an agent that interferes with DNA replication prior to vaccination with a survivin vaccine. Also provided are compositions for use in the methods of the invention.

Abstract: The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced Th1 response and wherein the compositions can be administered orally. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions.

Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).

Abstract: Provided are cytokine fusion proteins comprising a first cytokine fused to a second cytokine, for example, interleukin-2 (IL-2) or interferon-? (IFN-?) fused to the N-terminus of tumor necrosis factor-? (TNF-?), and related compositions and methods of use thereof for treating cancers, either as standalone agents or in combination with autologous tumor vaccines and/or immune checkpoint modulatory agents.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

Abstract: Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors. However, co-treatment with epigenetic modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of them. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). A PI3K-inhibitor that reduced circulating MDSCs also cured 80% of mice with metastatic 4T1 tumors when combined with immune checkpoint inhibitors. Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.

Abstract: The present invention relates to a cobalt-nitrosyl complex having photocleavable ligands. The cobalt-nitrosyl complex provided in one aspect of the present invention is adept in the delivery of NO, with exquisite temporal control using light, without gene editing. In addition, the complex provided in one aspect of the present invention is excellent in biocompatibility because it is chemically stable, non-toxic at cell level, and non-perturbative in cellular environments.